Colorectal cancer (CRC) is a major cause of tumor-related morbidity and mortality worldwide [
1,
2]. Progression of CRC can occur over decades and involves the early development of adenomatous precursor lesions followed by invasive stages of the disease [
3]. The poor prognosis associated with metastatic CRC underlines the increasing importance of developing efficacious strategies for early intervention including chemoprevention [
1,
2]. Indeed, chemopreventive intervention aiming at pharmaco-logical suppression of colon carcinogenesis has shown promise in cellular studies as well as in animal and human chemoprevention trials [
1,
4–
6].
Recent research suggests that pharmacological intervention using dietary factors that activate the redox sensitive Nrf2/Keap1-ARE signaling pathway may represent a promising strategy for chemoprevention of human cancer including CRC [
7–
9]. It has been shown that numerous chemopreventive factors act through covalent adduction and/or oxidation of redox-sensitive thiol residues in Keap1 (Kelch-like ECH-associated protein 1), the negative regulator of Nrf2 (nuclear factor-E2-related factor 2) [
10]. Inhibition of Keap1-dependent ubiquitination and subsequent proteasomal degradation of Nrf2 allows Nrf2 nuclear translocation, followed by Nrf2-dependent transcriptional activation of target genes containing an antioxidant response element (ARE)-promotor sequence. Upregulation of the cellular antioxidant and electrophilic stress response by Nrf2 has been shown to mediate Nrf2-dependent suppression of environmental toxicity and carcinogenesis [
8,
11–
14]. For example, it is well established that chemopreventive electrophiles, including the broccoli-derived isothiocyanate sulforaphane and the turmeric-derived β-diketone curcumin, activate signaling through the Nrf2/Keap1-ARE pathway upregulating the expression of many antioxidant and phase II-detoxification target genes, including heme oxygenase 1, γ-glutamyl cysteine synthetase (catalytic subunit), glutathione reductase, glutathione peroxidase, thioredoxin-1, thioredoxin reductase, and peroxiredoxins [
15,
16].
In our search for promising dietary Nrf2 activators with potential chemopreventive activity targeting CRC we have focused our studies on trans-cinnamic aldehyde (cinnamaldehyde, CA), the key flavor compound in cinnamon essential oil extracted from
Cinnamomum zeylanicum and
Cinnamomum cassia bark. Recently, our structure-activity relationship studies have revealed that the α,β-unsaturated aldehyde CA is a reactive Michael acceptor that spontaneously forms covalent adducts with model thiols and activates Nrf2-regulated antioxidant response element (ARE)-mediated gene expression [
17].
In cultured human skin cells, CA displayed photo-chemopreventive activity by suppressing reactive oxygen species (ROS)-induced photooxidative stress [
17]. In addition, anti-melanoma activity of orally administered CA was demonstrated recently in a murine xenograft model of the disease [
18], and cinnamaldehydes (including CA and its 2-hydroxy- and 2-benzoyloxy-substituted analogs) that inhibit thioredoxin reductase and activate Nrf2 have been examined as potential candidates for cancer therapy and chemoprevention [
19]. Oral administration of cinnamon has recently been shown to suppress azoxymethane-induced colon carcinogenesis in a mouse model, but the molecular identity of the bioactive constituents of cinnamon was not elucidated [
20]. Earlier studies have demonstrated antioxidant [
21], antimicrobial [
22], anti-inflammatory [
23], and anti-diabetic [
24] activities of cinnamon that were attributed to cellular effects of CA and other cinnamon ingredients including phenolic proanthocyanidins [
24–
26].
Remarkably, CA is the only α,β-unsaturated aldehyde which is FDA-approved for use in foods (21 CFR § 182.60) and given the ‘Generally Recognized As Safe’ status by the ‘Flavor and Extract Manufacturers’ Association (FEMA) in the United States (FEMA no. 2286, 2201). This suggests that a potential chemopreventive administration of this dietary factor may be achievable with an acceptable safety profile, an important prerequisite for the development of chemopreventive pharmacological strategies in healthy individuals [
27]. Here we demonstrate that CA and an ethanolic cinnamon extract with standardized CA content (CE) display potent activity as activators of Nrf2 transcriptional activity, Nrf2 protein upregulation, and Nrf2 target gene expression in human colon cancer and fetal colon cells. Moreover, CA and an ethanolic cinnamon extract induce the antioxidant defense in colon epithelial cells and elevate cellular glutathione levels resulting in increased resistance to oxidative insult from arsenic and hydrogen peroxide.